Table of contents


On 14 April 2004, orphan designation (EU/3/04/197) was granted by the European Commission to LungRx Limited, United Kingdom, for treprostinil sodium (inhalation use) for the treatment of pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension.

The sponsorship was transferred to United Therapeutics Europe Ltd, United Kingdom, in January 2008.

The sponsorship was transferred to Unither Therapeutik GmbH, Germany, in February 2019.

Key facts

Active substance
Treprostinil sodium (inhalation use)
Disease / condition
Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Date of first decision
EU designation number

Sponsor's contact details

Unither Therapeutik GmbH
Dreieichstrasse 11
64546 Moerfelden-Walldorf
Tel. +49 6105 27137

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
1 rating